Arthneeti
EL

ERIS Lifesciences Ltd

Q1 FY27Pharmaceuticals & Biotechnology

ERIS Lifesciences Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹1,310
Market cap₹18.4K Cr
P/E28.1
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 3 strong

RevenueRank 3
MarginRank 2
CapexYes

Not discussed on this call: fundraise, order book.

The short version

DBF segment delivered 14% revenue growth in Q1 FY27; aiming for 3% above market growth (~14% vs 11% market). Q1 FY27 Profit After Tax grew by 14.5%, with EPS at INR 10.3, indicating strong profitability (Page 16). - Domestic formulations (DBF) segment expects sustained 14%+ revenue growth, targeting 300 bps above market growth (~14% vs.

From ERIS Lifesciences Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3
  • DBF segment delivered 14% revenue growth in Q1 FY27; aiming for 3% above market growth (~14% vs 11% market).
  • Long-term goal to structurally achieve top-tier growth through portfolio shift towards biologics and insulin.
  • Insulin franchise shows strong market share gains and has significant growth potential from existing products and pipeline.
  • Semaglutide brand SUNDAE has captured 20% volume and 14% value market share in its first quarter.
  • Domestic formulations expected to see gross margin improvement by Q3-Q4 FY27 aiding EBITDA margins.
  • OAD segment growth expected to improve to 5-6% with product launches and ramp-up.
  • No inorganic growth activities planned currently; focus on organic growth and manufacturing capabilities.
  • International business impact neutral to low single-digit growth; export flattish.
  • Guidance: operating cash flow trend of around 77% of EBITDA to continue.

Profitability & Margins

See what ERIS Lifesciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • CapEx for Q1 FY27 stood at INR 88 crores.
  • Focus on manufacturing expansion with priority given to the Bhopal facility; commercialization expected in August with ramp-up by end of Q3 FY27.
  • Investment in manufacturing technology and facilities continues to be a priority over acquisitions for this year and the start of next year.
  • No major acquisitions planned currently; emphasis is on organic growth and strengthening manufacturing capacity.
  • CAPA actions for international sites are ongoing, aiming for audit readiness by December.
  • The shift to biologics and insulins, supported by manufacturing capabilities at Bhopal, is expected to drive medium-term growth and margin improvement.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what ERIS Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not specifically mention details about the current or expected order book or pending orders for Eris Lifesciences Limited. However, related operational insights include: - Bhopal manufacturing facility commercialization expected in August, with gradual product ramp-up through Q3. - Swiss Parenterals is experiencing softer growth with remediation work ongoing; expected to be neutral to low single-digit growth without major negative impact on revenue. - The company's domestic formulations business (DBF) is targeting 14% growth, outpacing the market by 300 basis points. - New product launches planned, including a major one in Q3. - Supply-side normalization noted post-initial excitement in insulin-related products. - No explicit mention or quantification of order book or pending orders was provided in the Q1 FY27 earnings call.

ERIS Lifesciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹757 Cr, net profit ₹279 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What ERIS Lifesciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were ERIS Lifesciences Ltd Q1 FY27 results?

DBF segment delivered 14% revenue growth in Q1 FY27; aiming for 3% above market growth (~14% vs 11% market). Q1 FY27 Profit After Tax grew by 14.5%, with EPS at INR 10.3, indicating strong profitability (Page 16). - Domestic formulations (DBF) segment expects sustained 14%+ revenue growth, targeting 300 bps above market growth (~14% vs.

What is ERIS Lifesciences Ltd share price analysis?

ERIS Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 28.1 with a market cap of ₹18,407 Cr. Investors should review the full earnings analysis for detailed insights.

Is ERIS Lifesciences Ltd planning capital expenditure?

CapEx for Q1 FY27 stood at INR 88 crores.

Keep ERIS Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.